In the past week, MTNB stock has gone down by -3.42%, with a monthly decline of -4.14% and a quarterly surge of 18.54%. The volatility ratio for the week is 20.72%, and the volatility levels for the last 30 days are 13.07% for Matinas Biopharma Holdings Inc The simple moving average for the last 20 days is -1.69% for MTNB stock, with a simple moving average of 9.70% for the last 200 days.
Is It Worth Investing in Matinas Biopharma Holdings Inc (AMEX: MTNB) Right Now?
Moreover, the 36-month beta value for MTNB is 1.53. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MTNB is 211.14M and currently, short sellers hold a 0.63% of that float. On April 01, 2024, MTNB’s average trading volume was 1.26M shares.
MTNB) stock’s latest price update
Matinas Biopharma Holdings Inc (AMEX: MTNB) has seen a decline in its stock price by -0.92 in relation to its previous close of 0.27. However, the company has experienced a -3.42% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-28 that Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Analysts’ Opinion of MTNB
Piper Sandler gave a rating of “Overweight” to MTNB, setting the target price at $3 in the report published on January 27th of the previous year.
MTNB Trading at 11.45% from the 50-Day Moving Average
After a stumble in the market that brought MTNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.83% of loss for the given period.
Volatility was left at 13.07%, however, over the last 30 days, the volatility rate increased by 20.72%, as shares sank -7.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.40% upper at present.
During the last 5 trading sessions, MTNB fell by -3.42%, which changed the moving average for the period of 200-days by -28.23% in comparison to the 20-day moving average, which settled at $0.2720. In addition, Matinas Biopharma Holdings Inc saw 24.19% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MTNB
Current profitability levels for the company are sitting at:
- -21.68 for the present operating margin
- 0.14 for the gross margin
The net margin for Matinas Biopharma Holdings Inc stands at -20.87. The total capital return value is set at -0.38. Equity return is now at value -82.11, with -31.77 for asset returns.
Based on Matinas Biopharma Holdings Inc (MTNB), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -4.3. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 325.56.
Currently, EBITDA for the company is -22.82 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 52.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.93.
Conclusion
To wrap up, the performance of Matinas Biopharma Holdings Inc (MTNB) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
